Wrapping up Q4 earnings, we look at the numbers and key takeaways for the senior health, home health & hospice stocks, including Chemed (NYSE: CHE) and its peers.

The senior health, home care, and hospice care industries provide essential services to aging populations and patients with chronic or terminal conditions. These companies benefit from stable, recurring revenue driven by relationships with patients and families that can extend many months or even years. However, the labor-intensive nature of the business makes it vulnerable to rising labor costs and staffing shortages, while profitability is constrained by reimbursement rates from Medicare, Medicaid, and private insurers. Looking ahead, the industry is positioned for tailwinds from an aging population, increasing chronic disease prevalence, and a growing preference for personalized in-home care. Advancements in remote monitoring and telehealth are expected to enhance efficiency and care delivery. However, headwinds such as labor shortages, wage inflation, and regulatory uncertainty around reimbursement could pose challenges. Investments in digitization and technology-driven care will be critical for long-term success.

The 7 senior health, home health & hospice stocks we track reported a slower Q4. As a group, revenues beat analysts’ consensus estimates by 1.1%.

Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 9.6% since the latest earnings results.

Weakest Q4: Chemed (NYSE: CHE)

With a unique business model combining end-of-life care and household services, Chemed (NYSE: CHE) operates two distinct businesses: VITAS, which provides hospice care for terminally ill patients, and Roto-Rooter, which offers plumbing and water restoration services.

Chemed reported revenues of $639.3 million, flat year on year. This print fell short of analysts’ expectations by 3%. Overall, it was a disappointing quarter for the company with a significant miss of analysts’ full-year EPS guidance estimates and a significant miss of analysts’ revenue estimates.

Chemed delivered the weakest performance against analyst estimates of the whole group. Unsurprisingly, the stock is down 19.2% since reporting and currently trades at $377.07.

Read our full report on Chemed here, it’s free.

Best Q4: BrightSpring Health Services (NASDAQ: BTSG)

Founded in 1974, BrightSpring Health Services (NASDAQ: BTSG) offers home health care, hospice, neuro-rehabilitation, and pharmacy services.

BrightSpring Health Services reported revenues of $3.55 billion, up 16.3% year on year, outperforming analysts’ expectations by 5%. The business had a strong quarter with a solid beat of analysts’ revenue estimates and full-year EBITDA guidance exceeding analysts’ expectations.

BrightSpring Health Services pulled off the biggest analyst estimates beat among its peers. The market seems happy with the results as the stock is up 6.1% since reporting. It currently trades at $42.59.

Is now the time to buy BrightSpring Health Services? Access our full analysis of the earnings results here, it’s free.

Option Care Health (NASDAQ: OPCH)

With a nationwide network of 177 locations serving 43 states and a team of over 4,500 clinicians, Option Care Health (NASDAQ: OPCH) is the largest independent provider of home and alternate site infusion services, delivering medications and clinical support to patients across the United States.

Option Care Health reported revenues of $1.47 billion, up 8.8% year on year, in line with analysts’ expectations. It was a slower quarter as it posted full-year revenue guidance slightly missing analysts’ expectations and EPS in line with analysts’ estimates.

As expected, the stock is down 20.6% since the results and currently trades at $28.66.

Read our full analysis of Option Care Health’s results here.

AdaptHealth (NASDAQ: AHCO)

With a network of approximately 680 locations serving patients across all 50 states, AdaptHealth (NASDAQ: AHCO) provides home medical equipment, supplies, and related services to patients with chronic conditions like sleep apnea, diabetes, and respiratory disorders.

AdaptHealth reported revenues of $846.3 million, down 1.2% year on year. This print topped analysts’ expectations by 2.1%. More broadly, it was a mixed quarter as it also produced an impressive beat of analysts’ revenue estimates but a significant miss of analysts’ EPS estimates.

AdaptHealth achieved the highest full-year guidance raise among its peers. The stock is up 3.2% since reporting and currently trades at $10.62.

Read our full, actionable report on AdaptHealth here, it’s free.

The Pennant Group (NASDAQ: PNTG)

Spun off from The Ensign Group in 2019 to focus on non-skilled nursing healthcare services, Pennant Group (NASDAQ: PNTG) operates home health, hospice, and senior living facilities across 13 western and midwestern states, serving patients of all ages including seniors.

The Pennant Group reported revenues of $288 million, up 52.6% year on year. This result beat analysts’ expectations by 4.6%. Taking a step back, it was a satisfactory quarter as it also logged a solid beat of analysts’ revenue estimates but a slight miss of analysts’ full-year EPS guidance estimates.

The Pennant Group scored the fastest revenue growth among its peers. The stock is down 5.2% since reporting and currently trades at $31.37.

Read our full, actionable report on The Pennant Group here, it’s free.

Market Update

Late in 2025 into early 2026, there was hand wringing around artificial intelligence. For software companies, the fear was that AI would erode pricing power and compress margins as new tools made it easier to replicate what once required expensive enterprise platforms. Crypto investors had their own version of the same anxiety: if AI agents could trade, allocate capital, and manage wallets autonomously, what exactly was the long-term value of today’s crypto infrastructure?

These concerns triggered a noticeable rotation away from these sectors and into safer havens. But markets rarely dwell on one narrative for long. Spring 2026 came, and the focus shifted abruptly from technological disruption to geopolitical risk. The US’ conflict with Iran became the dominant driver of market psychology, and when geopolitics takes center stage, the script changes quickly. Investors stop debating growth rates and start worrying about oil supply, inflation, and global stability.

Want to invest in winners with rock-solid fundamentals? Check out our Strong Momentum Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.